NCT04998825View on ClinicalTrials.gov

Efficacy and Tolerability of Proteoglycan F in the Treatment of Knee Osteoarthritis

NACompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

February 25, 2022

Study Completion Date

May 30, 2022

Conditions
Primary Osteoarthritis of Knee Nos
Interventions
DIETARY_SUPPLEMENT

Proteoglycan F

Salmon proteoglycan (Proteoglycan F) was extracted from salmon (Oncorhynchus keta) nasal cartilage. Salmon cartilage PG (Proteoglycan F) was manufactured in the form of a hard capsule by Ichimaru Pharcos, Co., Ltd. (at 318-1 Asagi, Motosu-shi, Gifu 501-0475 Japan) and consisted of 50 mg proteoglycan.

OTHER

Placebo product

The placebo capsule contained only dextrin powder (Ichimaru Pharcos, Co., Ltd.).

Trial Locations (2)

100000

National Geriatric Hospital, Hanoi

National Institution of Nutrition, Hanoi

All Listed Sponsors
collaborator

Ichimaru Pharcos, Co., Ltd.

UNKNOWN

lead

National Geriatric Hospital

OTHER_GOV

NCT04998825 - Efficacy and Tolerability of Proteoglycan F in the Treatment of Knee Osteoarthritis | Biotech Hunter | Biotech Hunter